What Has Been The Evolution of the Focal Segmental Glomerulosclerosis Drugs Market in Recent Years?
The focal segmental glomerulosclerosis drugs market has seen considerable growth due to a variety of factors.
• The market for drugs treating focal segmental glomerulosclerosis has seen robust growth in the past few years. It is projected to increase from $15.77 billion in 2024 to $17.08 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%.
This historic growth trend is due to factors such as the increased prevalence of the disease, higher demands for new treatment methods, a rising interest from the pharmaceutical industry, and enhanced government backing.
What Are the Future Growth Projections for the Focal Segmental Glomerulosclerosis Drugs Market?
The focal segmental glomerulosclerosis drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for drugs treating focal segmental glomerulosclerosis is set to experience significant growth over the coming years. It is projected to increase to $24.87 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.8%.
Factors driving this growth during the forecast period include research and development spending, increasing healthcare costs, heightened awareness and diagnosis, an aging population, as well as government initiatives and funding. Key trends during this forecast period involve technological progress in medicine discovery and development, the growth of the clinical trials pipeline, enhanced drug reimbursement schemes for focal segmental glomerulosclerosis treatments, and the expansion of company research facilities.
What Are The Core Factors Supporting Growth In The Focal Segmental Glomerulosclerosis Drugs Market?
The escalating incidents of kidney infections are anticipated to stimulate the expansion of the focal segmental glomerulosclerosis (FSGS) drugs market. Pyelonephritis, a severe form of urinary tract infection (UTI) affecting one or both kidneys, is driving the need for FSGS drugs. These specialized treatments for kidney diseases offer several positives in terms of managing the ailment and enhancing kidney performance by reducing proteinuria, slowing kidney damage progression, and enhancing the life quality of patients afflicted with kidney-related ailments. In July 2022, The Centers for Disease Control and Prevention, part of the US Department of Health and Human Services, reported about 15% (37 million) of the US population dealing with kidney diseases. In 2021, there was a 12% prevalence rate for individuals within the 45–64 age bracket and a 6% rate for those aged between 18 and 44. Therefore, the burgeoning rise in kidney infections acts as a driver for the focal segmental glomerulosclerosis (FSGS) market. The integral role of increasing healthcare expenditures in propelling the growth of the Focal Segmental Glomerulosclerosis (FSGS) Drugs Market:
What Are The Major Segments Within The Global Focal Segmental Glomerulosclerosis Drugs Market?
The focal segmental glomerulosclerosis drugs market covered in this report is segmented –
1) By Type: Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types
2) By Treatment: Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments
3) By Route of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Pre-Book The Focal Segmental Glomerulosclerosis Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Focal Segmental Glomerulosclerosis Drugs Market?
Key players in the focal segmental glomerulosclerosis (FSGS) market are progressively centering their efforts on product progression and novelty, aiming to offer dependable products to their clients and fortify their stand in the market. To illustrate, Travere Therapeutics, a biopharmaceutical firm based in the US, introduced FILSPARI, a medication for focal segmental glomerulosclerosis (FSGS) in February 2023. This product was sanctioned by the Food and Drug Administration (FDA), a federal agency in the US. FILSPARI is an orally taken medicine for addressing IgA nephropathy (IgAN) and is distinguished as the first and sole non-immunosuppressive treatment to reduce proteinuria in IgAN, a seldom-seen kidney ailment. Furthermore, both the US and Europe have granted FILSPARI orphan drug status for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS).
Who Are the Key Players In The Focal Segmental Glomerulosclerosis Drugs Market?
Major companies operating in the focal segmental glomerulosclerosis drugs market are:
• Pfizer Inc.
• Johnson and Johnson Ltd.
• F. Hoffmann-La Roche AG
• Bayer AG
• Novartis AG
• Sanofi S.A.
• Bristol Myers Squibb Company
• AstraZeneca PLC
• Fresenius Kabi Ltd.
• GSK PLC
• Medtronic Plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Astellas Pharma Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Mylan N.V.
• B. Braun Melsungen AG
• Hikma Pharmaceuticals PLC
• Alexion Pharmaceuticals
• Wockhardt
• Travere Therapeutics
• Aurinia Pharmaceuticals Inc.
• Omeros Corporation
• Dimerix Ltd.
• Goldfinch Bio.
What Is The Most Dominant Region In The Focal Segmental Glomerulosclerosis Drugs Market?
North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2024. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
